841 – 24 494)   Gendera Male

35 median 4 037 0 817 3 200

841 – 24.494)   Gendera Male

35 median 4.037 0.817 3.200 0.247 0.986 0.611 9.794 0.746 12.670 0.379       (range) (0.427 – 61.171)   (0.035 – 17.376)   (0.020 Talazoparib – 6.229)   (0.000 – 64.312)   (0.100 – 45.381)     {Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|buy Anti-infection Compound Library|Anti-infection Compound Library ic50|Anti-infection Compound Library price|Anti-infection Compound Library cost|Anti-infection Compound Library solubility dmso|Anti-infection Compound Library purchase|Anti-infection Compound Library manufacturer|Anti-infection Compound Library research buy|Anti-infection Compound Library order|Anti-infection Compound Library mouse|Anti-infection Compound Library chemical structure|Anti-infection Compound Library mw|Anti-infection Compound Library molecular weight|Anti-infection Compound Library datasheet|Anti-infection Compound Library supplier|Anti-infection Compound Library in vitro|Anti-infection Compound Library cell line|Anti-infection Compound Library concentration|Anti-infection Compound Library nmr|Anti-infection Compound Library in vivo|Anti-infection Compound Library clinical trial|Anti-infection Compound Library cell assay|Anti-infection Compound Library screening|Anti-infection Compound Library high throughput|buy Antiinfection Compound Library|Antiinfection Compound Library ic50|Antiinfection Compound Library price|Antiinfection Compound Library cost|Antiinfection Compound Library solubility dmso|Antiinfection Compound Library purchase|Antiinfection Compound Library manufacturer|Antiinfection Compound Library research buy|Antiinfection Compound Library order|Antiinfection Compound Library chemical structure|Antiinfection Compound Library datasheet|Antiinfection Compound Library supplier|Antiinfection Compound Library in vitro|Antiinfection Compound Library cell line|Antiinfection Compound Library concentration|Antiinfection Compound Library clinical trial|Antiinfection Compound Library cell assay|Antiinfection Compound Library screening|Antiinfection Compound Library high throughput|Anti-infection Compound high throughput screening| Female 5 median 4.331   1.454   1.191   9.102   19.520         (range) (3.223 – 6.581)   (0.677 – 7.218)   (0.562 – 2.361)   (5.989 – 12.900)   (5.367 – 23.448)   T classificationb 1 2 coefficient rs = -0.264 0.114 rs = 0.089 0.583 rs = -0.017 0.919 rs = 0.223 0.170 rs = -0.327 0.041*   2 10                         3 22                         4 6                       LN metastasisa N (-) 15 median 2.399 0.037* 2.926 0.964 0.983 0.800 6.947 0.226 18.801 0.020*       (range) (0.427 – 6.092)   (0.059 – 11.250)   (0.193 – 5.137)   (0.000 – 42.360)   (0.841 – 45.381)     N (+) 25 median 4.443   3.602   1.094   12.037   10.688         (range) (1.379 – 61.171)   (0.035 – 17.376)   (0.020 – 6.229)   (0.936 – 64.312)   (0.100 – 23.697)   Histological gradeb I 21 coefficient rs = 0.155 0.338 rs = 0.462 0.004* rs = 0.374

0.021* rs = 0.381 0.019* rs = -0.026 0.873   II 12                         III 7                       Vascular invasiona Negative 32 median 3.478 0.133 3.393 0.360 1.006 0.608 9.369 0.913 14.999 0.085       (range) (0.640 – 61.171)   (0.035 – 17.376)   (0.020 – 5.538)   (0.000 – 64.312)   (0.100 – 45.381)     Positive 8 median 10.759   2.250   1.264   9.794   7.799         (range) (0.427 – 43.355)   (0.059 Selleck NVP-BSK805 – 6.356) TCL   (0.193 – 6.229)   (1.246 – 29.053)   (0.841 – 23.697)   Lymphatic invasiona Negative 22 median 4.037 0.800 3.939 0.195 0.936 0.554 9.027 0.554 15.966 0.192       (range) (0.640 – 61.171)   (0.035 – 11.250)   (0 020 – 5.137)   (0.000 – 64.312)   (1.373 – 38.234)     Positive 18 median 4.733   2.155   1.104   10.915   10.694         (range) (0.427 – 60.921)  

(0.059 – 17.376)   (0.086 – 6.229)   (0.936 – 31.933)   (0.100 – 45.381)   Perineural invasiona Negative 30 median 4.128 0.841 2.212 0.016* 1.006 0.286 7.720 0.008* 14.891 0.617       (range) (0.427 – 61.171)   (0.035 – 11.250)   (0.020 – 5.137)   (0.000 0 64.312)   (0.100 – 38.234)     Positive 10 median 5.247   6.345   1.114   13.886   11.907         (range) (0.640 – 60.921)   (2.250 – 17.376)   (0.458 – 6.229)   (9.027 – 31.933)   (2.089 – 45.381)   aMann-Whithey U test, bSpearman rank correlation coefficient. Univariate and multivariate analyses of risk factors affecting lymph node metastasis To determine the risk factors predictive of lymph node metastasis, we further examined the correlation of lymph node metastasis with other clinicopathological factors. As shown in Table 3, advanced T-classification was significantly correlated with lymph node metastasis (p = 0.036).

Comments are closed.